Atypical antipsychotic use in a state hospital inpatient adolescent population.
暂无分享,去创建一个
R. Conley | D. Kelly | R. McMahon | R. Love | Marie Mackowick | R. Mcmahon
[1] A. Malhotra,et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. , 2006, Child and adolescent psychiatric clinics of North America.
[2] E. Liebelt. New drug therapies for diseases in children: from atypical antipsychotics to antivenom for snakebites. , 2005, Current opinion in pediatrics.
[3] R. Weizman,et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.
[4] R. Schweitzer,et al. "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. , 2002, Schizophrenia bulletin.
[5] C. Maffeis,et al. Long-Term Effects of Childhood Obesity on Morbidity and Mortality , 2001, Hormone Research in Paediatrics.
[6] S. Scott,et al. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. , 2001, The Journal of pediatrics.
[7] S. Gupta,et al. Risperidone-associated galactorrhea in a male teenager. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.
[8] J. Buitelaar,et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. , 2001, The Journal of clinical psychiatry.
[9] Duntas Lh. Prolactinomas in children and adolescents--consequences in adult life. , 2001 .
[10] S. Daniels. Pharmacological Treatment of Obesity in Paediatric Patients , 2001, Paediatric drugs.
[11] H. Parraga,et al. Quetiapine treatment of children with Tourette's syndrome: report of two cases. , 2001, Journal of child and adolescent psychopharmacology.
[12] S. Kutcher,et al. Update and recommendations for the use of antipsychotics in early-onset psychoses. , 2001, Journal of child and adolescent psychopharmacology.
[13] A. Cosenza,et al. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. , 2001, Journal of child and adolescent psychopharmacology.
[14] M. Tohen,et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. , 2001, Journal of child and adolescent psychopharmacology.
[15] J. Zislin,et al. Risperidone in treating behavioural disturbances of Prader‐Willi syndrome , 2000, Acta psychiatrica Scandinavica.
[16] J. Jureidini. Epidemic of schizophrenia in children or inappropriate prescribing? , 2000, The Medical journal of Australia.
[17] R. Findling,et al. Paediatric uses of atypical antipsychotics , 2000, Expert opinion on pharmacotherapy.
[18] M. Onofrj,et al. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide , 2000, Journal of Neurology.
[19] S. Aysun,et al. Weight gain associated with valproate in childhood. , 2000, Pediatric neurology.
[20] L. Wilkinson,et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. , 2000, The Journal of clinical psychiatry.
[21] M. Schluchter,et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.
[22] M. Salvatore,et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization , 2000, Clinical endocrinology.
[23] K. Chang,et al. Mood stabilizer augmentation with olanzapine in acutely manic children. , 2000, Journal of child and adolescent psychopharmacology.
[24] J. Buitelaar. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. , 2000, Journal of child and adolescent psychopharmacology.
[25] D. Cicchetti,et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. , 2000, Journal of child and adolescent psychopharmacology.
[26] P. Muglia,et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. , 2000, Journal of child and adolescent psychopharmacology.
[27] C. McDougle,et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. , 2000, Child and adolescent psychiatric clinics of North America.
[28] G. Kewley. Risperidone in comorbid ADHD and ODD/CD. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.
[29] J. Biederman,et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.
[30] P. Keck,et al. Olanzapine in the treatment of adolescent acute mania: a report of seven cases. , 1999, Journal of affective disorders.
[31] L. Burke,et al. Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.
[32] W. Glazer,et al. Neuroleptic-induced hyperprolactinemia , 1999, Schizophrenia Research.
[33] C. McDougle,et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. , 1999, Journal of clinical psychopharmacology.
[34] R. Malone,et al. Novel antipsychotic medications in the treatment of children and adolescents. , 1999, Psychiatric services.
[35] S. Stahl. Peptides and psychiatry, Part 1: How synthesis of neuropeptides differs from classical neurotransmitter synthesis. , 1999, The Journal of clinical psychiatry.
[36] J. Rapoport,et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. , 1999, Journal of child and adolescent psychopharmacology.
[37] G. Hanna,et al. Separation anxiety in children and adolescents treated with risperidone. , 1999, Journal of child and adolescent psychopharmacology.
[38] J. Bregman,et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. , 1999, Journal of child and adolescent psychopharmacology.
[39] J. Mccombs,et al. Use patterns for antipsychotic medications in medicaid patients with schizophrenia. , 1999, The Journal of clinical psychiatry.
[40] D. Rosenberg,et al. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. , 1999, Journal of child and adolescent psychopharmacology.
[41] J. Rapoport,et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. , 1998 .
[42] R. Conley,et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. , 1998, Journal of child and adolescent psychopharmacology.
[43] H. Schreier. Risperidone for young children with mood disorders and aggressive behavior. , 1998, Journal of child and adolescent psychopharmacology.
[44] S. Fisman,et al. Risperidone in PDD. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.
[45] G. Bates,et al. Movement disorder with fluoxetine. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.
[46] C. McDougle,et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.
[47] J. Gorman,et al. Risperidone in adolescents with schizophrenia: an open pilot study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.
[48] J. Busner,et al. Prescribing practices of inpatient child psychiatrists under three auspices of care. , 1997, Journal of child and adolescent psychopharmacology.
[49] C. Pataki,et al. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. , 1997, Journal of child and adolescent psychopharmacology.
[50] D. Safer. Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. , 1997, Journal of child and adolescent psychopharmacology.
[51] J. Rapoport,et al. Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison , 1996 .
[52] Charles M Beasley,et al. Olanzapine versus Placebo and Haloperidol , 1996, Neuropsychopharmacology.
[53] S. Weiss,et al. Lithium and Body Weight Gain , 1995, Pharmacopsychiatry.
[54] B. Grannemann,et al. Clozapine Treatment of Children and Adolescents with Bipolar Disorder and Schizophrenia: A Clinical Case Series , 1995 .
[55] J. Rapoport,et al. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.
[56] A. Roche,et al. The predictive value of childhood body mass index values for overweight at age 35 y. , 1994, The American journal of clinical nutrition.
[57] H. Remschmidt,et al. An Open Trial of Clozapine in Thirty-Six Adolescents with Schizophrenia , 1994 .
[58] Abraham Weizman,et al. Clozapine treatment in very early onset schizophrenia. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.
[59] W. Dietz,et al. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. , 1992, The New England journal of medicine.
[60] H. Meltzer,et al. Platelet imipramine binding in depressed children and adolescents. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.
[61] S. Kapur,et al. Clozapine for the treatment of adolescents with schizophrenia. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.
[62] A Tremblay,et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. , 1990, Arteriosclerosis.
[63] D Kromhout,et al. Body Mass Index at the age of 18 and its effects on 32-year-mortality from coronary heart disease and cancer. A nested case-control study among the entire 1932 Dutch male birth cohort. , 1989, Journal of clinical epidemiology.
[64] T. Van Itallie,et al. Obesity: adverse effects on health and longevity. , 1979 .
[65] G. Bray,et al. Obesity: a serious symptom. , 1972, Annals of internal medicine.